Entheogenics
Why the Psychedelic Experience May Be Part of the Medicine
Add MyCannabis.com to your preferred sources on Google
Psychedelic medicine faces a deceptively simple question: if scientists can preserve a drug’s effects on the brain while eliminating the trip, should they?
A new analytical essay published in the International Journal of Drug Policy argues that doing so may remove more than an inconvenient side effect.1 The authors contend that subjective experience, emotional insight, social connection, and the surrounding environment may be central to how psychedelic therapies produce lasting change.
This debate reaches beyond psilocybin and LSD. Cannabis has already confronted a similar tension between isolating specific compounds and preserving the complex experience of using a psychoactive plant. Its history shows both the value of pharmaceutical standardization and the risks of assuming that a molecule alone explains every therapeutic outcome.
What Are Psychoplastogens?
Psychoplastogens are compounds designed to promote neuroplasticity, meaning the brain’s ability to form and reorganize neural connections. Classic psychedelics such as psilocybin, LSD, and DMT appear to encourage this plasticity, but they also produce substantial changes in perception, mood, and consciousness.
Those subjective effects create practical challenges. A conventional psychedelic session can last several hours and may require preparation, continuous supervision, and follow-up integration. The paper notes that some clinical protocols use two therapists for every patient. That makes treatment expensive and difficult to deliver at scale.
Drug developers are therefore investigating compounds that retain neuroplastic effects while reducing or eliminating hallucinations. One engineered LSD analogue, described in preclinical research published in 2025, reportedly stimulated neuronal growth and produced antidepressant-like effects in animals while showing reduced hallucinogenic potential.
MyCannabis previously examined similar research involving a non-hallucinogenic psilocybin-inspired drug. These developments suggest that researchers may be able to separate at least some biological effects of psychedelic compounds from their more disruptive psychological effects.
However, evidence that a compound changes neurons or animal behaviour does not establish that it can reproduce the therapeutic outcomes of a guided psychedelic experience in humans. The new essay argues that this distinction is being overshadowed by the commercial appeal of trip-free medicine.
Why Removing the Trip Is Commercially Attractive
A trip-free psychedelic could fit more easily into the existing pharmaceutical system. It might be prescribed like a conventional medication, administered without an all-day appointment, and manufactured as a standardized product. It could also reduce acute risks for patients who might experience panic, confusion, or psychological distress during an altered state.
The potential advantages include:
- Shorter and less labour-intensive treatment
- More predictable dosing and patient responses
- Access for some people who cannot use classic psychedelics
- Easier integration with insurance and regulatory systems
These are legitimate goals. Greater scalability could allow more people to receive treatment, while a non-hallucinogenic option may be appropriate for patients who do not want or cannot safely tolerate an intense psychedelic experience.
The concern is that commercial convenience may be mistaken for therapeutic equivalence. A medicine that is easier to patent, standardize, and sell is not automatically capable of producing the same outcome as the treatment it was designed to replace.
| Approach | Primary Focus | Central Trade-Off Identified by the Paper |
|---|---|---|
| Classic psychedelic therapy | Drug effects combined with subjective experience | Potentially transformative but costly and difficult to scale |
| Psychoplastogens | Neuroplasticity with reduced or absent hallucinations | Easier to standardize but may remove a therapeutic mechanism |
| Ecodelic model | Personal, social, and ecological connection | Preserves context but does not fit easily into conventional drug delivery |
The Case That Experience Is Part of the Treatment
The paper disputes the idea that a psychedelic experience is merely neurological noise surrounding a useful biochemical event. Instead, it presents psychedelics as non-specific amplifiers whose effects depend heavily on what a person brings into the experience and what surrounds them during and after it.
Set, Setting, and Matrix
Set refers to a person’s mindset, expectations, emotional condition, and intentions. Setting includes the physical and social environment in which the experience occurs. The authors add a third factor called matrix, meaning the wider cultural, relational, and ecological world to which the person returns.
A supportive session may open a temporary period of psychological flexibility. Preparation can help direct that flexibility, while integration can translate an unusual experience into changes in habits, beliefs, or relationships. Neuroplasticity may create the opportunity for change, but experience and context may influence what fills that opportunity.
This interpretation is supported by a 2025 systematic review and meta-analysis that found the intensity of psychedelic experiences was associated with clinical improvement. Association does not prove that the trip caused the improvement, but it makes the subjective component difficult to dismiss.
The distinction matters because psychedelic therapy may operate differently from a medication designed to suppress a symptom continuously. The altered state can allow patients to confront entrenched beliefs, experience emotional catharsis, or perceive themselves and their relationships differently. Removing that state could preserve neural activity while losing the narrative process that gives it meaning.
What Cannabis Can Teach Psychedelic Medicine
Cannabis offers an instructive comparison because it has been transformed from a traditional plant medicine into both a commercial consumer product and a source of standardized pharmaceuticals.
Researchers can isolate THC, CBD, and other cannabinoids, measure their receptor activity, and deliver them in controlled doses. This has clear advantages for clinical research and prescribing. At the same time, many cannabis consumers report that whole-plant products feel different from isolated cannabinoids because chemovar, terpene profile, dose, consumption method, expectations, and environment can all affect the experience.
The proposed cannabis entourage effect remains scientifically contested, and it should not be treated as proof that whole plants are always therapeutically superior. Still, the cannabis experience demonstrates that isolating an active compound answers only one type of question. It can clarify what a molecule does while leaving open how a complete product, person, and environment interact.
Cannabis also proves that intoxication and therapeutic value do not have a single relationship. CBD can produce effects without the intoxicating experience associated with THC. Some patients actively avoid impairment, while others report that changes in sensation, mood, sleep, or pain perception are inseparable from the relief they seek.
Likewise, psychedelics and cannabis should not be treated as pharmacologically interchangeable. Research indicates that psilocybin and cannabis affect the brain differently. The useful comparison is not that both substances work through the same mechanism. It is that both challenge the assumption that therapeutic value can always be reduced to one compound acting independently of dose, experience, and context.
Standardization Can Protect Patients Without Defining Healing
The answer does not need to be a choice between pharmaceutical precision and experiential care. Cannabis markets already contain multiple models, including isolated compounds, standardized extracts, whole-flower products, and clinician-guided treatment. Psychedelic medicine could similarly develop several distinct lanes.
Non-hallucinogenic psychoplastogens may become useful medications in their own right. Classic psychedelic-assisted therapy could remain a separate intervention for patients who may benefit from guided subjective experiences. Community-based or group models could also be investigated rather than excluded simply because they are difficult to reproduce within a conventional drug trial.
Each model should be evaluated according to what it claims to deliver. If a psychoplastogen is presented as an antidepressant, it should demonstrate meaningful clinical benefits in human trials. It should not be assumed to reproduce the full effects of psychedelic-assisted therapy merely because it promotes neuroplasticity in animals.
The cannabis sector provides a related warning about allowing consumer enthusiasm and commercial claims to move faster than evidence. As discussed in what psilocybin microdosing can learn from cannabis, popularity does not establish efficacy, and standardized products do not eliminate the need for accurate claims, testing, and patient education.
The Trip-Free Debate Is Really About the Definition of Medicine
The paper introduces the idea of ecodelics, which frames psychedelics as catalysts for connection with oneself, other people, communities, and the natural world. From this perspective, healing does not happen exclusively inside the brain. It emerges through the relationship between pharmacology, consciousness, and the world surrounding the patient.
This is also where the paper becomes more argumentative than experimental. It is a critical review and essay, not a clinical trial comparing psychoplastogens with psychedelic-assisted therapy. It cannot establish that trip-free compounds will fail. Its stronger contribution is identifying a question that future trials must not avoid: are researchers measuring the entire therapeutic intervention or only the part that fits most easily into pharmaceutical development?
Taking the trip out of psychedelic medicine may produce treatments that are safer, cheaper, and more accessible. Those treatments could still prove valuable. However, if emotional insight, connection, and meaning are active ingredients rather than incidental reactions, trip-free medicines should be understood as a new class of treatment, not automatically as simplified versions of the same one.
Cannabis has shown that pharmaceutical isolates and complex plant experiences can coexist without one fully replacing the other. Psychedelic medicine may need the same pluralism. The goal should not be to preserve altered states for their own sake, but to determine honestly which elements create benefit, which create risk, and which are being removed primarily because they are difficult to monetize.
References:
1 Heller, J., & Hendlin, Y. H. (2026). Why taking the trip out of psychedelic medicine is a mistake. International Journal of Drug Policy, 157, 105487. https://doi.org/10.1016/j.drugpo.2026.105487
